V2X Expands Army Training Support with $921 Million BEST MAC Contract
RESTON, Va., March 26, 2025 /PRNewswire/ -- V2X (NYSE: VVX) Inc., announced its selection as a winner on the Bridge to Enduring Synthetic Training Environment Tactical Engagement Simulation Systems (TESS) Multiple-Award Contract (BEST MAC) Lot 1. This contract supports the U.S. Army's TESS devices, a vital component of its live training capabilities, by extending their product life and ensuring they meet the Army's evolving requirements.
The indefinite-delivery, indefinite-quantity contract includes a ten-year period of performance consisting of a five-year base period and two options (three-year option and a two-year option), with a ceiling value of $921 million.
Under this award, V2X will support the U.S. Army's TESS products that are designed to enable simulated engagements, either as weapons or targets, during live collective military training exercises. These devices include weapons, vehicles, and aviation systems. Existing TESS must be modified to stay relevant as changes to weapon systems evolve.
"The BEST MAC contract perfectly complements the work we perform under our $3.7 billion Warfighter-Training Readiness Solutions task order," said Jeremy C. Wensinger, President and Chief Executive Officer at V2X. "Both programs demonstrate our commitment to the warfighter and our expertise in delivering readiness capabilities that enhance Army training and strengthen national security."
"As the prime contractor for the Army's largest training services program, V2X is uniquely positioned to deliver superior services that align with BEST MAC future requirements," said Ken Shreves, Senior Vice President of Mission Support at V2X. "Our dedication to the Army goes beyond operational excellence—we are committed to reinforcing national security through mission-critical initiatives and ensuring troops are prepared worldwide."
About V2XV2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission's lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today's toughest challenges across all operational domains.
Investor Contact Mike Smith, CFAVice President, Treasury, Corporate Development and Investor RelationsIR@goV2X.com719-637-5773
Media ContactAngelica Spanos DeoudesSenior Director, Marketing and Communications Angelica.Deoudes@goV2X.com571-338-5195
View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-expands-army-training-support-with-921-million-best-mac-contract-302411041.html
SOURCE V2X, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
GXO Logistics taps new CEO, clears acquisition of Wincanton
GXO Logistics Inc. recently announced two significant developments focused on shaping its future growth trajectory. The company has appointed a new chief executive officer and received clearance from the United Kingdom Competition and Markets Authority (CMA) for its acquisition of Wincanton. Patrick Kelleher was named CEO on Friday. He will begin his tenure on Aug. 19 and will be based at the company's Greenwich, Connecticut. GXO Logistics (NYSE: GXO) is one of the largest pure-play contract logistics providers in the world. It has more than 150,000 team members across more than 1,000 facilities totaling more than 200 million square feet. 'Patrick is a world-class operator with the relevant experience to lead GXO through its next phase of growth,' Brad Jacobs, chairman of GXO's board of directors, said in a news release. Kelleher will bring 33 years of global supply chain experience to GXO, having held senior executive roles at DHL Supply Chain. Most recently, he served as CEO for North America at DHL. GXO Logistics also announced that the CMA has cleared the company's acquisition of Wincanton. The approval comes with specific conditions, requiring the divestment of a small number of Wincanton grocery contracts in the UK, according to a news release. GXO is acquiring Wincanton for about $1 billion. Wincanton is a major logistics and supply chain operator in the U.K. and Ireland. GXO and Wincanton's integration is expected to begin in the third quarter. The company also updated its full-year 2025 guidance: Organic revenue growth of 3.5% to 6.5% (up from 3% to 6%) Adjusted earnings before interest, taxes, depreciation, and amortization of $860 million to $880 million (up from $840 million to $860 million) Adjusted earnings per share of of $2.43 to $2.63 (up from $2.40 to $2.60) The post GXO Logistics taps new CEO, clears acquisition of Wincanton appeared first on FreightWaves. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22 minutes ago
- Business Wire
Deadline Alert: Vestis Corporation (VSTS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Vestis Corporation ('Vestis' or the 'Company') (NYSE: VSTS) securities between May 2, 2024, to May 6, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR VESTIS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On May 7, 2025, Vestis released its second quarter fiscal 2025 financial results and revised its prior growth and revenue guidance for 2025, providing guidance for the third quarter, falling significantly below market expectations. The Company explained that the poor results were partially due to 'lost business in excess of new business' but primarily on 'lower adds over stops, which is how [it] describe[s] volumes changes with [its] existing customers.' On this news, Vestis's stock price fell $3.27, or 37.5%, to close at $5.44 per share on May 7, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was not equipped to achieve its growth guidance as the realization of these efforts instead resulted in a significant decline of revenue from existing customers; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Vestis securities during the Class Period, you may move the Court no later than August 8, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
27 minutes ago
- Yahoo
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Lilly is acquiring an exciting new program with the agreement to buy Verve Therapeutics. The terms of the deal mean there is still upside for investors, provided Lilly can take VERVE-102 to a phase 3 trial. 10 stocks we like better than Verve Therapeutics › Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. The deal centers on an exciting cardiovascular health medicine program, VERVE-102. It's easy to see why Lilly is excited about the program. VERVE-102 targets the PCSK9 gene, aiming to deactivate it in the liver, and achieves this with a single infusion. Given that PCSK9 binds to low-density lipoprotein (LDL) (often called "bad" cholesterol) receptors and prevents them from recycling to the cell surface, it follows that inhibiting PCSK9 will improve the body's ability to remove bad cholesterol. The initial results from the phase 1b trial give cause for optimism. According to Verve's press release: "VERVE-102 was well-tolerated, with no treatment-related serious adverse events (SAEs) and no clinically significant laboratory abnormalities observed" across 14 patients given three different dose levels. Dose dependency was established, with the lowest dose (0.3mg/kg) patients achieving a "mean reduction in blood LDL-C of 21%," rising to 41% at the 0.45mg/kg dose, and 53% at the 0.6mg/kg dose. Lilly is offering: $10.50 per share for all the outstanding shares Plus a nontradable contingent value right (CVR) that pays up to $3 per share upon "the first patient being dosed with VERVE-102 for ASCVD in a U.S. phase 3 clinical trial on or prior to the tenth anniversary of closing or termination of the CVR." The share price is $11.12 as I write, implying that the market is willing to pay $0.62 for the CVR, suggesting a 21% chance that Lily will take VERVE-102 to a stage 3 trial -- a reasonable assumption for a novel medicine under a major pharmaceutical company. Before you buy stock in Verve Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Verve Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
